Keppra
Imitrex
Copegus
Citalopram |
||
|
FOREST LABS * FOREST LABORATORIES INC AEROSPAN HFA, FLUNISOLIDE BYSTOLIC, NEBIVOLOL HYDROCHLORIDE CAMPRAL, ACAMPROSATE CALCIUM CELEXA, CITALOPRAM HYDROBROMIDE COMBUNOX, IBUPROFEN ELIXOPHYLLIN, THEOPHYLLINE FLUMADINE, RIMANTADINE HYDROCHLORIDE LEXAPRO, ESCITALOPRAM OXALATE NAMENDA, MEMANTINE HYDROCHLORIDE TESSALON, BENZONATATE THYROLAR-0.25, LIOTHYRONINE SODIUM THYROLAR-0.5, LIOTHYRONINE SODIUM THYROLAR-1, LIOTHYRONINE SODIUM THYROLAR-2, LIOTHYRONINE SODIUM.
Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Cefaclor Monohydrate Cefadroxil Cefpodoxime Proxetil Cefuroxime Axetil CEFZIL CELEBREX CELESTONE 0.6 mg 5ml SYRP CELEXA 10 mg 5ml SOLN CELLCEPT CELONTIN CENESTIN Cephalexin Cephradine CERUMENEX CETAPRED OINT CETROTIDE CHLOR PSEUDO SR Chloral Hydrate Chlordiazepoxide HCl Chlordiazepoxide-Amitriptyline Chlorhexidine Gluconate Mouth-Throat ; CHLOROPTIC 0.5 % SOLN Chloroquine Phosphate Chlorothiazide Chlorphen Tan & Pseudoeph Tan Chlorpheniramine & Phenylephrine Chlorpheniramine & Pseudoeph Chlorpheniramine Maleate Chlorpheniramine Tannate-Carbetapentane Tannate Chlorpheniramine Tannate-Phenylephrine Tannate Chlorpheniramine-Methscopolami ne Chlorpheniramine-Pseudoephedri ne & Belladonna Alkaloids Chlorpheniramine-Pseudoephedri ne & Methscopolamine Chlorpheniramine-Pyrilamine & Phenylephrine Chlorphen-PE-Atropine-Hyoscya mine-Scopolamine Chlorphen-Phenyleph w APAP Chlorphen-Phenyltolox-PE Chlorpromazine HCl Chlorpropamide Chlorthalidone Chlorzoxazone Cholestyramine Cholestyramine Light Choline & Mag Salicylate Ciclopirox Olamine Cilostazol CILOXAN Cimetidine Cimetidine HCl CIPRO HC Ciprofloxacin HCl Ciprofloxacin HCl Ophth ; Citalorpam Hydrobromide Clemastine Fumarate CLEOCIN CLEOCIN Clidinium & Chlordiazepoxide CLIMARA CLINDAGEL Clindamycin HCl Clindamycin Phosphate Topical ; Clioquinol-HC Clobetasol Propionate Clobetasol Propionate Emollient Base CLODERM Clomiphene Citrate Clomipramine HCl Clonazepam Clonidine HCl Clorazepate Dipotassium CLORPRES Clotrimazole Clotrimazole Topical ; Clotrimazole w Betamethasone Cloxacillin Sodium Clozapine Cobalamine Combinations Codeine-Guaifenesin COLAZAL Colchicine Colchicine w Probenecid COLESTID COLESTID FLAVORED COLY-MYCIN S COLY-MYCIN-S COMBIPATCH COMBIVENT COMBIVIR COMPAZINE COMTAN 200 mg TABS CONDYLOX 0.5 % GEL COPAXONE COPEGUS CORDRAN CORDRAN SP COREG CORTANE-B LOTN CORTEF CORTIFOAM 90 mg FOAM Cortisone Acetate CORTISPORIN COSOPT COZAAR CRESTOR CRIXIVAN Cromolyn Sodium Cromolyn Sodium Ophth ; CUPRIMINE CUTIVATE 0.05 % CREA Cyclobenzaprine HCl CYCLOGYL CYCLOMYDRIL Cyclopentolate HCl Cyclophosphamide Cyclosporine Cyclosporine Modified For Microemulsion ; Cyproheptadine HCl CYTADREN 250 mg TABS CYTOMEL CYTOVENE Desmopressin Acetate Refrigerated Desmopressin Acetate Spray Refrigerated Desogestrel & Ethinyl Estradiol Desogestrel-Ethinyl Estradiol Triphasic ; Desonide Desoximetasone DESPEC SR TB12 DETROL LA Dexamethasone Dexamethasone Sodium Phosphate Ophth ; Dexbrompheniramine & Pseudoephedrine Dexchlorpheniramine Maleate Dexchlorpheniramine Tannate & Pseudoephedrine Tannate Dextroamphetamine Sulfate Dextromethorphan-GG-Sodium Citrate Dextromethorphan-Guaifenesin Dextromethorphan-Potassium Guaiacolsulfonate DIAMOX DIASTAT Diazepam Diclofenac Potassium Diclofenac Sodium Dicloxacillin Sodium Dicyclomine HCl DIDRONEL Diethylpropion HCl DIFFERIN Diflorasone Diacetate Diflorasone Diacetate Emollient Base DIFLUCAN Diflunisal Digestive Aids Mixture Digoxin DILANTIN DILANTIN INFATABS DILATRATE SR DILOR 160 mg 15ml ELIX Diltiazem HCl Diltiazem HCl Coated Beads Diltiazem HCl Extended Release Beads Dimenhydrinate DIOVAN DIOVAN HCT DIPENTUM Diphenhydramine HCl Diphenhydramine Tannate-Phenylephrine Tannate Diphenoxylate w Atropine Dipivefrin HCl DIPROSONE 0.1 % AERS Dipyridamole Disopyramide Phosphate DITROPAN XL DIURIL 250 mg 5ml SUSP DOLOBID 250 mg TABS DONNATAL EXTENTABS DOVONEX Doxazosin Mesylate Doxepin HCl Doxepin HCl Antipruritic ; Doxycycline Monohydrate ; Doxycycline Hyclate DRITHO-SCALP 0.5 % CREA DROXIA DUAC GEL DUONEB DURAGESIC DURATUSS GP TB12 DYNACIRC DYNACIRC CR Dyphylline Dyphylline-Guaifenesin DYRENIUM. It is anticipated that the ongoing development of the industry relationship with Asthma Australia will Janine will develop and build relationships with ensure that there is appropriate support provided health consumer organisations and. provide a channel for two way communication, ensuring that to the community, and that the broader issues health care issues are clearly understood from both regarding the provision of medicines to consumers in Australia are better understood. consumer and industry perspectives! Having said that, it is important that you maintain a good fluid intake as reducing fluids too much can lead to very concentrated urine which in turn can irritate the lining of the bladder.
9. Personne M, Persson H, Sjoberg G: Cialopram toxicity. Lancet 1997; 350: 518519. Personne M, Sjoberg G, Persson H. Citxlopram overdose-- Review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997; 35: 237240. Boeck V, Fredricson OK, Svendsen O: Studies on acute toxicity and drug levels of citalopram in the dog. Acta Pharmacol Toxicol 1982; 50: 169174. Burgh Van Der M. Citzlopram product monograph. Copenhagen, Denmark: H Lundbeck A S, 1994. 13. Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS lett 2002; 512: 5966 and haldol. Citalopram what is itRausch JL, Corley KM, Hobby HM. Improved potency of escitalopram on the human serotonin transporter -- Demonstration of an ex vivo assay technique. Journal of Clinical Psychopharmacology. 2004; 24 2 ; : 209-213. Smith GS, Ma Y, Dhawan V, et al. Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography PET ; in human subjects. Synapse. 2002; 45 2 ; : 105-112. Smith GS, Kramer E, Haermann CR, et al. Acute and chronic effects of citalopram on cerebral glucose metabolism in geriatric depression. Am.J.Geriatr.Psychiatry. 2002; 10: 715-723. Drevets WC. Functional neuroimaging studies of depression: the anatomy of melancholia. Annual Review of Medicine. 1998; 49: 341-361. Hariri AR, Bookheimer SY, Mazziotta JC. Modulating emotional responses: effects of a neocortical network on the limbic system. NeuroReport. 2000; 11 1 ; : 43-48. Mattay VS, Callicott JH, Bertolino A, et al. Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage. 2000; 12 3 ; : 268-275. Hariri AR, Mattay VS, Tessitore A, Fera F, Smith WG, Weinberger DR. Dextroamphetamine modulates the response of the human amygdala. Neuropsychopharmacology. 2002; 27 6 ; : 1036-1040. Loubinoux I, Boulanouar K, Ranjeva JP, et al. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. Journal of Cerebral Blood Flow & Metabolism. 1999; 19 12 ; : 1365-1375. Loubinoux I, Pariente J, Boulanouar K, et al. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebocontrolled, fMRI study in healthy subjects. Neuroimage. 2002; 15 1 ; : 26-36. Fu CHY, Williams SCR, Cleare AJ, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment -- A prospective, event-related functional magnetic resonance imaging study. Archives of General Psychiatry. 2004; 61: 877-889. Del-Ben CM, Deakin JFW, McKie S, et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an fMRI study. Neuropsychopharmacology. 2005; 30: 1724-1734. Cooper J, Bloom F, Roth R. The biochemical basis of neuropharmacology. 7th ed. New York: Oxford University Press; 1996. Mazzanti CM, Lappalainen J, Long JC, et al. Role of the serotonin transporter promoter polymorphism in anxiety-related traits. Archives of General Psychiatry. 1998; 55 10 ; : 936940. Katsuragi S, Kunugi H, Sano A, et al. Association between serotonin transporter gene polymorphism and anxiety-related traits. Biological Psychiatry. 1999; 45 3 ; : 368-370. Greenberg BD, Li Q, Lucas FR, et al. Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample. American Journal of Medical Genetics Neuropsychiatric Genetics ; . 2000; 96: 202-216. Melke J, Landen M, Baghei F, et al. Serotonin transporter gene polymorphisms are associated with anxiety-related personality traits in women. American Journal of Medical Genetics Neuropsychiatric Genetics ; . 2001; 105: 458-463. Citalopram also appears to beefficacious as an adjunctive treatment for depressed subjects who remainsymptomatic after treatment with e2 i and trazodone! Study Aguglia et al., 1993 171 Davidson, 2002 172 Entsuah et al., 2001 153 Feiger, 2003 173 Gorman et al., 2002 174 Oslin et al., 2003152 Stahl, 2000 175 Stahl, 2002 176 Design RCT Pooled analysis Metaanalysis Pooled analysis Metaanalysis RCT RCT Pooled analysis Randomized single-blind parallel Pooled analysis RCT Metaanalysis RCT RCT RCT RCT Sample Intervention size Major depressive disorder 108 Sertraline vs. fluoxetine 1097 2045 Venlafaxine vs. fluoxetine Venlafaxine, paroxetine, fluoxetine, placebo Sertraline vs. fluoxetine Escitalopram vs. citalopram Venlafaxine vs. sertraline Citalopram vs. sertraline vs. placebo Venlafaxine fluoxetine paroxetine placebo Fluoxetine vs. sertraline Venlafaxine vs. SSRI vs. placebo Mirtazapine vs. paroxetine MDD-Ped Fluoxetine vs. placebo Fluoxetine vs. placebo Fluoxetine vs. placebo Bipolar Venlafaxine vs. paroxetine Fluoxetine vs. imipramine vs. Placebo Reason for exclusion High loss to follow-up; High differential loss to follow-up No systematic literature search No systematic literature search No systematic literature search No systematic literature search High loss to follow-up High loss to follow-up No systematic literature search Single-blinded No systematic literature search High loss to follow-up No systematic literature search Loss to follow-up differential 15 percentage points Loss to follow-up differential 15 percentage points Single-blinded High loss to follow-up. DISCUSSION Antidepressants, particularly serotonergic reuptake inhibitors have proved effective in treating PTSD, and have been recommended as first-line agents in treatment guidelines Davidson et al., 2001; Brady et al., 2000; Foa et al., 2000; Foa et al., 1999 ; . Sertraline is the best-studied of the SSRIs, with four studies of over 100 participants each showing a significant response to the drug Brady et al., 2000; Davidson et al., 2001b; Londborg et al., 2001; Rapaport et al., 2002 ; . Significantly, the FDA has approved sertraline for the treatment of PTSD, and it is likely that other serotonergic drugs will be given FDA approval as the results of ongoing multicenter studies become available. Paroxetine has also been FDA approved, and two large studies Marshall et al., 2001; Tucker et al., 2001 ; have demonstrated its usefulness in treating PTSD. Fluoxetine has also been shown to be useful Barnett et al., 2002; Connor et al., 1999; Malik et al., 1999; Martenyi et al., 2002a; Martenyi et al., 2002b; Meltzer-Brody, et al., 2000 ; . Citalopram and fluvoxamine have been less studied, although they too show promise for reducing PTSD symptoms. Other medications used in PTSD include anticonvulsants, mood stabilizers lithium ; , anxiolytics benzodiazepines, beta-blockers and beta-adrenergic agonists ; , and other antidepressants monoamine oxidase inhibitors and tricyclic antidepressants ; . In clinical practice there is a tendency to use polypharmacy in the treatment of PTSD, and also to use medications in conjunction with psychosocial treatments. However, studies examining the efficacy of these combined approaches area currently lacking Halligan & Yehuda, 2001 ; . In a Cochrane Review, Stein et al. 2000 ; report on 22 RCTs in the pharmacological treatment of PTSD. Chronic PTSD was the primary diagnosis included in these studies; however, several addressed DESNOS and complex PTSD. The most common types of trauma studied were military combat, sexual abuse as a child or adult, physical abuse as a child or adult, or witnessing of a traumatic event. Also included were individuals who experienced accidents or natural disasters, or were the victims of a violent crime, torture, or terror. Seventeen of the 22 RCT of pharmacological management of PTSD involved SSRIs n 8 ; , MAOIs n 5 ; , TCAs n 3 ; and trazodone n 1 ; . Trials with SSRIs generally were of 12 weeks or longer and used clinicianadministered evaluation of response. Overall, the antidepressant studies using global assessment e.g., Clinical Global Improvement ; and individual symptom assessment e.g., intrusion, avoidance, hyperarousal ; reported that drug treatment produced both statistically and clinically significantly reductions in symptoms compared to placebo. However, it is important to note that patients were rarely rated as "complete responders." A meta-analysis of 4 RCTs that compared SSRIs to placebo without regard to diagnostic criteria, duration, severity, or co-morbid diagnoses reported that treatment favored the drug in all 4 trials; however, only one study with 183 subjects ; reached statistical significance. Two RCTs maintained treatment with an SSRI for 64 weeks and 40 weeks, respectively. One study reported that 50% of patients experienced worsening symptoms when placebo was substituted for active drug and in the second report patients on placebo were 6.4 times more likely to relapse compared to the drug group. Although some patients may respond to an antidepressant trial within 3 months, some patients may require more than 12 weeks to respond to SSRIs Martenyi et al 2002 ; . Stein et al. 2000 ; note that for TCAs 3 studies ; and MAOIs 5 studies ; , methodological limitations of early trials included short-duration 5 weeks or less ; and reliance on self-administered rating scales. Of the TCAs, nortriptyline is the only recently-studied drug Dow et al., 1997; Zygmont et al., 1998 ; . In a small study, Zygmont and his colleagues found the drug to be helpful in reducing traumatic grief symptoms 1998 Dow et al. found improvement in CGE for dual diagnosis after nortriptyline 1997 ; . In the MAOI category, Neal et al. 1997 ; report significant improvement in symptoms in a small sample with the use of moclobemide, and Connor et al. 2001 ; report significant improvement in CAPS scores with brofaromine. In meta-analysis evaluations dropout rates between SSRIs, TCAs, and MAOIs secondary to drug side effects did not differ among the 3 groups or placebo Stein et al., 2000 ; . Sympatholytics have also been investigated as PTSD therapy. Of the sympatholytics, prazosin and propranolol have been the subject of recent studies. In four relatively small studies Raskind et al., 2003; Raskind et al., 2002; Raskind et al., 2000; Taylor & Raskind, 2002 ; , prazosin has demonstrated a value in reducing nightmares and in and celexa. Hypersensitivity to citalopram or to any of the excipients. Citalopram should not be given to patients receiving Monoamine Oxidase Inhibitors MAOIs ; including selegiline in daily doses exceeding 10 mg day. Citalopram should not be given for fourteen days after discontinuation of an irreversible MAOI or for the time specified after discontinuation of a reversible MAOI Reversible Monoamine oxidase type A, RIMA ; as. Recent research has suggested that psoriasis is caused by a weakening of the 'gut wall' or intestine which leaks toxins into the bloodstream and zyprexa. 6 esourcer moderator healthy living join date: apr 2005 location: gta, ontario canada - 1, 175 offline: it's not so basic, and easily confused, as some as you are i believe. It is virtually impossible to keep medical records in a way that makes treatment decisions easy and risperdal. Citalopram drug infoGeneric Name fluoxetine sertraline paroxetine citalopram escitalopram Tri-cyclic desipramine imipramine nortriptyline doxepin amitriptyline Norpramin Pertofrane Tofranil Aventyl Pamelor Sinequan Adapin Elavil 150 - 300 150 - 300 75 - 100 150 - 300 150 - 300 Dry mouth, tremors, blurred vision Bloating and weight gain, Urinary retention, Lightheadedness on standing up suddenly, Sweating Constipation, Change in sexual desire High dose: irregular heartbeat Can be lethal: Use with caution Weight Gain Dizziness Sleep disturbances Impaired sexual functioning Swelling of legs and ankles Weight loss, agitation, risk of seizures. Very sedating; used in lower doses for insomnia. Activating, headache sleepiness, nausea, constipation Headache, sleepiness, agitation, nausea, tremor, constipation Increased appetite, weight gain, sleepiness, dizziness Brand Name Prozac Zoloft Paxil Celexa Lexapro Usual Dose mg. ; 20 - 40 50 - 200 10 - 50 20 - Side Effects SSRI: Most frequently prescribed type of anti-depressant Anxiety Nausea Headaches Weight Loss Activating rather than sedating; may trigger mania or psychosis. Lethality level low. Evidence of effectiveness of citalopram combined with 1mg risperidone or alone Dr C maintained that there is evidence in the literature that citalopram is effective in treating psychotic symptoms when combined with a reduced dose neuroleptic such as risperidone. He cited two studies: Kallionieme, H and Syvaelahti, E, "Citalopram, A Specific Inhibitor of Serotonin Reuptake in Treatment of Psychotic and Borderline Patients", Nordic Journal of Psychiatry 1993 ; 47 Supp 28 ; : 390393 the Kallionieme study ; . Pollock, B G, Mulsant, B H, Rosen, J, et al, "Comparison of Citalopram, Perphenazine, and Placebo for the Acute Treatment of Psychosis and Behavioral Disturbances in Hospitalized, Demented Patients", J Psychiatry 2002 ; 159 3 ; : 460465 the Pollock study and wellbutrin and Citalopram online.
` 0.007 ; and a greater change from baseline 0.012 ; than the PROP-treated subjects during phase A. There were no significant differences between drugs during phase B. The number of patients who crossed diabetes diagnostic limits was studied according to accepted standards that define the 2-hour OGTT as definitely normal below 140 mg dl and definitely abnormal above 199 mg dl . ` The percentage change in each of these cate * gories in those subjects who completed each phase is shown in Figure 2. In 80 HCTZ-treated subjects completing phase A, there were 21% fewer with a definitely normal O.OOOl ; , and 11% more with a definitely abnormal 0.027 ; , 2-hour OGTT result than at baseline. Both differences were also significant between drugs Cp 0.0002 and p 0.039 respectively ; . During phase B the only significant difference was in the 45 HCTZ-treated subjects: 22% fewer subjects had a definitely normal 2-hour OGTT result than at baseline p 0.016 ; . However, this difference was not significant between drugs.
|